Project Grant R01AG084718
Award Date
6/15/24
Completion Date
2/28/29
Dollars Obligated
$1.5M
Federal Agency
National Institute on Aging
Federal Grant Program
93.866
Assistance Type
Project Grant
Place of Performance
Cincinnati, OH 45221, USA
Similar Awards
The University of Rochester received a $423,500 Project Grant award from the National Institute on Aging (CFDA 93.866 Aging Research program) to investigate the role of mitochondrial dysfunction and oxidative stress in the progression of tau pathology in Alzheimer's disease. The two-year project will utilize novel optogenetic tools to spatiotemporally control mitochondrial function and reactive oxygen species production in both ex vivo brain slice cultures and an in vivo mouse model of tau...
This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $652,575 to New York University School of Medicine to investigate how pathological tau protein disrupts the endosomal microautophagy (EMI) pathway in Alzheimer's disease. The 2-year project, running from August 2024 to April 2026, aims to elucidate the role of tau in destabilizing EMI through mitochondrial disruption and aberrant binding or sequestration of key EMI components. The...
This Project Grant award from the National Institute on Aging (CFDA 93.866 Aging Research) in the amount of $408,638 will fund research at Virginia Commonwealth University to investigate the effects of pathogenic tau protein accumulation on hippocampal neurons in Alzheimer's disease and other neurodegenerative diseases. The research aims to elucidate the specific subtypes of hippocampal neurons that are vulnerable to tau-mediated neurodegeneration, and to determine the impact on network...
This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $242,310 to Emory University to conduct research aimed at understanding the role of interneuron dysfunction and pathological tau protein in the early stages of Alzheimer's disease. The key objectives of the project are to: Determine how pathological tau affects the excitability of neurons, and how this relates to hyperexcitability observed in Alzheimer's disease models. Investigate...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $1,709,482 to the Seattle Institute for Biomedical and Clinical Research to investigate how the SUT-6/NIPP1 protein regulates pathological tau, a key factor in Alzheimer's disease and other neurodegenerative "tauopathies." The 5-year project aims to: 1) Define the functions of SUT-6/NIPP1 important for suppressing tau toxicity; 2) Determine downstream mediators of SUT-6/NIPP1's...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $2,061,909 to Weill Medical College of Cornell University to conduct research on tau proteostasis and chaperone complexes in tauopathies, including Alzheimer's disease. The objective is to identify molecular mechanisms underlying tau protein aggregation and tau-related neurodegeneration, with a focus on how two specific chaperone complexes (the "foldase" complex and the...
The National Institutes of Health's National Institute on Aging awarded $3.468 million to The Trustees of Columbia University under the Aging Research grant program (CFDA 93.866) for the period September 15, 2022 through August 31, 2025. The project aims to investigate the role of PTEN-induced putative kinase 1 (PINK1) in abnormal tau accumulation and related mitochondrial dysfunction and neuroinflammation in Alzheimer's disease and related tauopathies. Specifically, the university researchers...
This $519,750 Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) supports a 2-year research study by the J. David Gladstone Institutes, a non-profit biomedical research organization in San Francisco. The study aims to explore the underlying molecular mechanisms by which reducing levels of the tau protein can prevent or diminish excitation/inhibition imbalance and network hyperexcitability in the brain. This imbalance has been observed in various...
This Project Grant award, identified as R21AG089708, was provided by the National Institute on Aging under the Aging Research federal grant program (CFDA 93.866). The award, totaling $660,000.00, will fund research to investigate the mechanisms by which amyloid-beta (Aβ) modulates the binding and internalization of pathological tau oligomers (TauO) at synapses, which is a key component of tau pathology spreading in Alzheimer's disease. The University of Texas Medical Branch at Galveston is the...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $472,500.00 to the J. David Gladstone Institutes to conduct research on using hypoxic (low oxygen) therapy to treat mitochondrial diseases. The research aims to expand the understanding of how hypoxia can prevent and reverse neurological damage caused by mitochondrial electron transport chain deficiencies. The project will investigate two potential mechanisms: activation of the hypoxia-inducible...